Insulin icodec/semaglutide

Insulin icodec/semaglutide
Combination of
Insulin icodec	Insulin analog
Semaglutide	GLP-1 receptor agonist
Clinical data
ATC code	None;

Last updated February 18, 2025

Insulin icodec/semaglutide is an experimental fixed-dose combination of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk.^[1]^[2]^[3]

References

↑ Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin (August 2021). "Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)". Diabetes Therapy. 12 (8): 2133–2147. doi:10.1007/s13300-021-01113-y. ISSN 1869-6953. PMC 8342688 . PMID 34268675.
↑ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 5 November 2023.
↑ Doctorx (12 February 2020). "Novo Nordisk's Insulin Products, Pipeline May Energize The Stock (NYSE:NVO) | Seeking Alpha". seekingalpha.com. Retrieved 5 November 2023.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin (August 2021). "Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)". Diabetes Therapy. 12 (8): 2133–2147. doi:10.1007/s13300-021-01113-y. ISSN 1869-6953. PMC 8342688 . PMID 34268675.

[2] "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 5 November 2023.

[3] Doctorx (12 February 2020). "Novo Nordisk's Insulin Products, Pipeline May Energize The Stock (NYSE:NVO) | Seeking Alpha". seekingalpha.com. Retrieved 5 November 2023.

[1]

[2]

[3]